Evidence map›Paper›PMID 32573787›Full record

ReviewPhotochemistry and photobiology2020

Photodynamic Therapy and Immune Checkpoint Blockade

Gwendolyn M Cramer, Edmund K Moon, Keith A Cengel, Theresa M Busch

Open access · bronzeAbstract readReview
In one paragraph

Review in Photochemistry and photobiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Recent development of nanomaterials-based PDT to improve immunogenic cell death.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2024
    Review
  12. Article
  13. PDT and antitumor immunity: the beginnings of the story.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2024
    Review
  14. Review
  15. The Latest Look at PDT and Immune Checkpoints.Current issues in molecular biology · 2024
    Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Gwendolyn M CramerDepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-1141-3391
Edmund K MoonDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Keith A CengelDepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0001-6960-5882
Theresa M BuschDepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-5499-8377
University of Pennsylvania · US

Funding

TUMOR HYPOXIA, PHOTOSENSITIZER, VASCULARITY AND PDTP01CA087971 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BUSCH, THERESA M, CENGEL, KEITH A · 2001 to 2019
$24.8M
Photodynamic therapy with prior inhibition of epidermal growth factor receptor to stimulate antitumor innate immune responseR01CA236362 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BUSCH, THERESA M · 2019 to 2023
$2.2M
Treating high grade intraepithelial lesions of the anus with photodynamic therapyR21CA223366 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BEN-JOSEF, EDGAR, BUSCH, THERESA M · 2018 to 2019
$380k
NCI NIH HHS P01 CA087971NCI NIH HHS P01-CA087971NCI NIH HHS R01 CA236362NCI NIH HHS R01-CA236362NCI NIH HHS R21 CA223366NCI NIH HHS R21-CA223366
6 · The paper itself

Abstract

Immune checkpoints including PD-1 and CTLA-4 help to regulate the intensity and timeframe of the immune response. Since they become upregulated in cancer and prevent sufficient antitumor immunity, monoclonal antibodies against these checkpoints have shown clinical promise for a range of cancers. Multimodal treatment plans combining immune checkpoint inhibitors with other therapies, including photodynamic therapy (PDT), may help to expand treatment efficacy and minimize side effects. PDT's cytotoxic effects are spatially limited by the light activation process, constraining PDT direct effects to the treatment field. The production of damage-associated molecular patterns and tumor-associated antigens from PDT can encourage accumulation and maturation of antigen-presenting cells and reprogram the tumor microenvironment to be more susceptible to therapies targeting immune checkpoints.

Indexed as

PhotochemotherapyAntineoplastic AgentsB7-H1 AntigenCTLA-4 AntigenHumansImmune Checkpoint InhibitorsImmunologic FactorsNeoplasmsTumor MicroenvironmentAntineoplastic AgentsB7-H1 AntigenCD274 protein, humanCTLA-4 AntigenCTLA4 protein, humanImmune Checkpoint InhibitorsImmunologic Factors

Identifiers

PMID32573787
PMCPMC12435613
OpenAlexW3037848606

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.